Displaying items by tag: division of neuro oncology

Ninety-two percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months. Glioblastoma multiforme is the most aggressive type of cancer originating in the brain.
Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.
Tagged under